Published in Rheumatology (Oxford) on September 16, 2012
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis. Mediators Inflamm (2013) 0.95
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther Adv Musculoskelet Dis (2013) 0.89
Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther (2013) 0.87
Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol (2013) 0.87
The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol (2013) 0.85
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis (2014) 0.85
Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator. Inflammation (2014) 0.81
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging (2016) 0.79
The shared crosstalk of multiple pathways involved in the inflammation between rheumatoid arthritis and coronary artery disease based on a digital gene expression profile. PLoS One (2014) 0.79
Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population-based Nord-Trøndelag health study (HUNT). Arthritis Res Ther (2014) 0.79
Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology (Oxford) (2015) 0.79
Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies. Arthritis (2014) 0.78
Differences in the prevalence and characteristics of metabolic syndrome in rheumatoid arthritis and osteoarthritis: a multicentric study. Rheumatol Int (2015) 0.78
[Treatment of cardiovascular risk factors]. Z Rheumatol (2016) 0.76
Co-morbidity index in rheumatoid arthritis: time to think. Clin Rheumatol (2015) 0.76
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. J Med Case Rep (2015) 0.76
Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis (2016) 0.76
The beneficial effects of Tai Chi exercise on endothelial function and arterial stiffness in elderly women with rheumatoid arthritis. Arthritis Res Ther (2015) 0.75
Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey. PLoS One (2017) 0.75
Impaired Left Ventricular Diastolic Functions and Thickened Epicardial Adipose Tissue in Rheumatoid Arthritis Patients is Correlated with DAS-28 Score. Acta Cardiol Sin (2017) 0.75
The Prevalence of Atherosclerosis in Those with Inflammatory Connective Tissue Disease by Race, Age, and Traditional Risk Factors. Sci Rep (2016) 0.75
Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. Ther Adv Musculoskelet Dis (2016) 0.75
Rheumatoid arthritis - an update for general dental practitioners. Br Dent J (2016) 0.75
Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis. Arthritis Rheumatol (2016) 0.75
Does depression increase the risk of stroke in patients with rheumatoid arthritis? A population-based cohort study. BMJ Open (2017) 0.75
Insulin Resistance in Early Rheumatoid Arthritis Is Associated with Low Appendicular Lean Mass. Biomed Res Int (2017) 0.75
Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol (2017) 0.75
The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis. Clin Rheumatol (2014) 0.75
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J (2003) 17.80
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Elevated C-reactive protein levels in overweight and obese adults. JAMA (1999) 9.94
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Indices of relative weight and obesity. J Chronic Dis (1972) 6.60
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA (2012) 5.17
Smoking and risk of rheumatoid arthritis. J Rheumatol (1993) 3.63
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum (2009) 3.58
The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol (2004) 3.29
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol (2006) 3.18
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest (1995) 3.14
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol (2006) 2.80
Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med (1994) 2.74
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 2.70
Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med (2006) 2.60
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis (2007) 2.46
Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum (2003) 2.29
Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol (2007) 2.18
The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis (2005) 2.18
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA (2007) 2.17
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis (2011) 2.01
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2009) 1.99
Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol (2007) 1.90
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis (2007) 1.73
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis (2004) 1.73
The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol (2000) 1.69
Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol (2012) 1.69
A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med (1993) 1.68
Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine (2007) 1.68
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum (2008) 1.63
Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation (2004) 1.62
Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis (2006) 1.56
Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes (2004) 1.53
Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) (2010) 1.53
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med (2005) 1.49
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis (2007) 1.46
Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis (2007) 1.46
Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum (2006) 1.38
Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine (2010) 1.37
Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol (2007) 1.36
Obesity in rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.32
Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci (2006) 1.32
Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One (2010) 1.32
Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther (2006) 1.31
Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil (2009) 1.30
Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis (2009) 1.27
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol (2010) 1.27
Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum (2001) 1.26
Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology (Oxford) (2007) 1.24
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol (2005) 1.22
Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2011) 1.22
Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis (2010) 1.21
Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum (2010) 1.21
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med (1990) 1.18
Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. J Rheumatol (2005) 1.16
Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis (2007) 1.14
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol (2006) 1.14
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2008) 1.12
Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol (2010) 1.12
Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol (2006) 1.10
Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol (2006) 1.08
Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum (2008) 1.06
A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol (2010) 1.03
Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis (2010) 1.02
Comparison of energy expenditure from lifestyle physical activities between patients with rheumatoid arthritis and healthy controls. Arthritis Rheum (2007) 0.97
Are patients with rheumatoid arthritis less physically active than the general population? J Clin Rheumatol (2007) 0.96
Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res (2002) 0.95
Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid (2004) 0.89
The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol (2009) 0.85
Inflammation associated with obesity: relationship with blood and bone marrow endothelial cells. Obesity (Silver Spring) (2011) 0.84
Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum (2009) 0.83
Prevalence of obesity among adults with arthritis --- United States, 2003--2009. MMWR Morb Mortal Wkly Rep (2011) 0.83
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
Incentives for drug development--the curious case of colchicine. N Engl J Med (2010) 3.06
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
Development of classification and response criteria for rheumatic diseases. Arthritis Rheum (2006) 2.88
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol (2006) 2.51
Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis (2013) 2.42
Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum (2007) 2.41
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med (2011) 2.35
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30
Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther (2011) 2.24
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA (2011) 2.17
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Measuring concurrent adherence to multiple related medications. Am J Manag Care (2009) 1.88
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol (2005) 1.83
Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol (2007) 1.80
Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum (2013) 1.80
Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum (2004) 1.76
Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc (2011) 1.76
The patient's perspective on the recall of Vioxx. J Rheumatol (2006) 1.71
Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken) (2013) 1.70
Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken) (2010) 1.68
Effectiveness of clinical pathways for total knee and total hip arthroplasty: literature review. J Arthroplasty (2003) 1.68
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 1.68
Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control (2007) 1.66
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res (2013) 1.66
Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med (2007) 1.62
Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol (2006) 1.60
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum (2006) 1.60
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J (2013) 1.60
Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry. J Rheumatol (2013) 1.59
At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood) (2010) 1.59
The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol (2012) 1.58
Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) (2011) 1.57
Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum (2009) 1.56
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther (2011) 1.55
Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) (2010) 1.53
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis (2011) 1.51
Patterns of bone mineral density testing: current guidelines, testing rates, and interventions. J Gen Intern Med (2004) 1.50
Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther (2010) 1.48
Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers. Med Care (2007) 1.47
The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther (2009) 1.45
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med (2008) 1.45
Identification and validation of vertebral compression fractures using administrative claims data. Med Care (2009) 1.45
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry (2010) 1.43
Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res (2006) 1.43
Coxibs, science, and the public trust. Arch Intern Med (2005) 1.43
The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther (2006) 1.43
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics (2010) 1.40
The end of rheumatoid factor as we know it? Arthritis Rheum (2011) 1.39
Cancer and the risk of suicide in older Americans. J Clin Oncol (2008) 1.33
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 1.31
Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf (2010) 1.31
Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Arch Intern Med (2003) 1.31
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Medical device innovation--is "better" good enough? N Engl J Med (2011) 1.26
Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum (2002) 1.26
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 1.25
Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care (2010) 1.25
Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments. Arthritis Res Ther (2011) 1.25
Improving the pharmacologic management of pain in older adults: identifying the research gaps and methods to address them. Pain Med (2011) 1.25
Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol (2010) 1.24
Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. Arthritis Care Res (Hoboken) (2015) 1.23
Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther (2012) 1.22
Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol (2005) 1.22
Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol (2005) 1.20
Bone mineral density in subjects using central nervous system-active medications. Am J Med (2005) 1.19
Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample. J Clin Endocrinol Metab (2007) 1.18
The MeTeOR trial (Meniscal Tear in Osteoarthritis Research): rationale and design features. Contemp Clin Trials (2012) 1.17
Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum (2003) 1.17
End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum (2011) 1.17
Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res (2011) 1.16
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One (2012) 1.14
Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum (2005) 1.13
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J (2008) 1.10
Rheumatoid arthritis decision making: many information sources but not all rated as useful. J Clin Rheumatol (2011) 1.09
Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther (2008) 1.08
Alcohol consumption and risk of incident rheumatoid arthritis in women: a prospective study. Arthritis Rheumatol (2014) 1.05
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Ann Rheum Dis (2012) 1.05
Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med (2002) 1.04